Cardiome Pharma Corp. (USA) (NASDAQ:CRME)
CAPS Rating:
Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.
RSS Headlines
Fool UK
Recs
Have long liked their lead compound. This should be a good year for cardiome-the partnership with Merck is great news.